Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T,
Chiappori A, Lee KH, de Wit M, et al (2017) Durvalumab after
Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J
Med 377, 1919-1929.
Arbour KC and Riely GJ (2019) Systemic Therapy for Locally Advanced and
Metastatic Non-Small Cell Lung Cancer: A Review. JAMA 322, 764-774.
Belani CP and Group TAXS (2002) Docetaxel in combination with platinums
(cisplatin or carboplatin) in advanced and metastatic non-small cell
lung cancer. Semin Oncol 29, 4-9.
Bennardo N, Cheng A, Huang N and Stark JM (2008) Alternative-NHEJ is a
mechanistically distinct pathway of mammalian chromosome break
repair. PLoS Genet 4, e1000110.
Blagosklonny MV and Fojo T (1999) Molecular effects of paclitaxel: Myths and
reality (a critical review). International Journal of Cancer 83, 151156.
Brandsma I and Gent DC (2012) Pathway choice in DNA double strand break
repair: observations of a balancing act. Genome Integr 3, 9.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
68, 394-424.
Bromberg KD, Mitchell TR, Upadhyay AK, Jakob CG, Jhala MA, Comess KM, Lasko
LM, Li C, Tuzon CT, Dai Y, et al (2017) The SUV4-20 inhibitor A-196
verifies a role for epigenetics in genomic integrity. Nat Chem Biol
13, 317-324.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O,
Agarwal N, Olmos D, et al (2020) Olaparib for Metastatic CastrationResistant Prostate Cancer. N Engl J Med 382, 2091-2102.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM,
Seto T, Cho BC, Tosi D, et al (2020) Entrectinib in patients with
advanced or metastatic NTRK fusion-positive solid tumours: integrated
analysis of three phase 1-2 trials. Lancet Oncol 21, 271-282.
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE,
39
Gautschi O, Besse B, Cho BC, et al (2020) Efficacy of Selpercatinib
in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 383,
813-824.
Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James
N, Farrington PM, Karmokar A, Willis SE, Cairns J, et al (2019)
AZD7648 is a potent and selective DNA-PK inhibitor that enhances
radiation, chemotherapy and olaparib activity. Nat Commun 10, 5065.
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K,
Gorbunova V, Kowalyszyn RD, Pikiel J, et al (2014) Ramucirumab plus
docetaxel versus placebo plus docetaxel for second-line treatment of
stage IV non-small-cell lung cancer after disease progression on
platinum-based therapy (REVEL): a multicentre, double-blind,
randomised phase 3 trial. Lancet 384, 665-673.
Gottesman M (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53,
615-627.
Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, Typas D,
Lammers M, Mailand N, Nussenzweig A, et al (2018) DNA Repair Network
Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP
Inhibitor Sensitivity. Cell 173, 972-988 e923.
Han TL, Sha H, Ji J, Li YT, Wu DS, Lin H, Hu B and Jiang ZX (2021) Depletion
of Survivin suppresses docetaxel-induced apoptosis in HeLa cells by
facilitating mitotic slippage. Sci Rep 11, 2283.
Heijink AM, Krajewska M and van Vugt MA (2013) The DNA damage response
during mitosis. Mutat Res 750, 45-55.
Henriques AC, Silva PMA, Sarmento B and Bousbaa H (2021) Antagonizing the
spindle assembly checkpoint silencing enhances paclitaxel and
Navitoclax-mediated apoptosis with distinct mechanistic. Sci Rep 11,
4139.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH,
Morise M, Felip E, Andric Z, Geater S, et al (2020) Atezolizumab for
First-Line Treatment of PD-L1–Selected Patients with NSCLC. New
England Journal of Medicine 383, 1328-1339.
Herbst RS, Heymach JV and Lippman SM (2008) Lung cancer. N Engl J Med 359,
1367-1380.
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu Y-L and Paz40
Ares L (2017) Lung cancer: current therapies and new targeted
treatments. The Lancet 389, 299-311.
Hyun SY, Rosen EM and Jang YJ (2012) Novel DNA damage checkpoint in mitosis:
Mitotic DNA damage induces re-replication without cell division in
various cancer cells. Biochem Biophys Res Commun 423, 593-599.
Jimenez-Guerrero R, Gasca J, Flores ML, Perez-Valderrama B, Tejera-Parrado
C, Medina R, Tortolero M, Romero F, Japon MA and Saez C (2018)
Obatoclax and Paclitaxel Synergistically Induce Apoptosis and
Overcome Paclitaxel Resistance in Urothelial Cancer Cells. Cancers
(Basel) 10.
Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, Ikeda S, Suzuki T
and Matsuda T (2021) Updated Trends in Cancer in Japan: Incidence in
1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer
Incidence. J Epidemiol 31, 426-450.
Kennedy MPT, Cheyne L, Darby M, Plant P, Milton R, Robson JM, Gill A,
Malhotra P, Ashford-Turner V, Rodger K, et al (2018) Lung cancer
stage-shift following a symptom awareness campaign. Thorax 73, 11281136.
Lara-Gonzalez P, Westhorpe FG and Taylor SS (2012) The spindle assembly
checkpoint. Curr Biol 22, R966-980.
Li J, Sun H, Huang Y, Wang Y, Liu Y and Chen X (2019) Pathways and assays
for DNA double-strand break repair by homologous recombination. Acta
Biochim Biophys Sin (Shanghai) 51, 879-889.
Lindahl T and Barnes DE (2000) Repair of endogenous DNA damage. Cold Spring
Harb Symp Quant Biol 65, 127-133.
Lok TM, Wang Y, Xu WK, Xie S, Ma HT and Poon RYC (2020) Mitotic slippage is
determined by p31(comet) and the weakening of the spindle-assembly
checkpoint. Oncogene 39, 2819-2834.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Jr.,
Srimuninnimit V, Laktionov KK, Bondarenko I, et al (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1expressing, locally advanced or metastatic non-small-cell lung cancer
(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet 393, 1819-1830.
Nan G, Zhao SH, Wang T, Chao D, Tian RF, Wang WJ, Fu X, Lin P, Guo T, Wang
41
B, et al (2022) CD147 supports paclitaxel resistance via interacting
with RanBP1. Oncogene 41, 983-996.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J,
Viteri S, Senellart H, Van Meerbeeck J, et al (2020) Tepotinib in
Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N
Engl J Med 383, 931-943.
Parkin DM, Bray F, Ferlay J and Pisani P (2005) Global cancer statistics,
2002. CA Cancer J Clin 55, 74-108.
Pena-Blanco A, Haschka MD, Jenner A, Zuleger T, Proikas-Cezanne T, Villunger
A and Garcia-Saez AJ (2020) Drp1 modulates mitochondrial stress
responses to mitotic arrest. Cell Death Differ 27, 2620-2634.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Perol M,
Dziadziuszko R, Rosell R, et al (2017) Alectinib versus Crizotinib in
Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 377,
829-838.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F,
Kim TM, Mazieres J, Novello S, et al (2016) Dabrafenib plus
trametinib in patients with previously treated BRAF(V600E)-mutant
metastatic non-small cell lung cancer: an open-label, multicentre
phase 2 trial. Lancet Oncol 17, 984-993.
Raab M, Kobayashi NF, Becker S, Kurunci-Csacsko E, Kramer A, Strebhardt K
and Sanhaji M (2020) Boosting the apoptotic response of high-grade
serous ovarian cancers with CCNE1 amplification to paclitaxel in
vitro by targeting APC/C and the pro-survival protein MCL-1. Int J
Cancer 146, 1086-1098.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried
M, Peled N, Tafreshi A, Cuffe S, et al (2016) Pembrolizumab versus
Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J
Med 375, 1823-1833.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W,
Tung N, Armstrong A, et al (2017) Olaparib for Metastatic Breast
Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377,
523-533.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R
and Johnson DH (2006) Paclitaxel-carboplatin alone or with
42
bevacizumab for non-small-cell lung cancer. N Engl J Med 355, 25422550.
Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ,
Varella-Garcia M, Shapiro GI, Costa DB, et al (2014) Crizotinib in
ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371, 19631971.
Shi JF, Wang L, Wu N, Li JL, Hui ZG, Liu SM, Yang BY, Gao SG, Ren JS, Huang
HY, et al (2019) Clinical characteristics and medical service
utilization of lung cancer in China, 2005-2014: Overall design and
results from a multicenter retrospective epidemiologic survey. Lung
Cancer 128, 91-100.
Sinha D, Duijf PHG and Khanna KK (2019) Mitotic slippage: an old tale with a
new twist. Cell Cycle 18, 7-15.
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A,
Schuler M, Borghaei H, Barlesi F, et al (2021) Sotorasib for Lung
Cancers with KRAS p.G12C Mutation. N Engl J Med 384, 2371-2381.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N,
Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous
NSCLC. N Engl J Med 378, 2288-2301.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee
KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung
Cancer. N Engl J Med 378, 113-125.
Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, Kumar S,
Pandey M, Singh RK, Ray P, et al (2012) An inhibitor of nonhomologous
end-joining abrogates double-strand break repair and impedes cancer
progression. Cell 151, 1474-1487.
Stanlie A, Yousif AS, Akiyama H, Honjo T and Begum NA (2014) Chromatin
reader Brd4 functions in Ig class switching as a repair complex
adaptor of nonhomologous end-joining. Mol Cell 55, 97-110.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray
F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of
Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA
Cancer J Clin 71, 209-249.
43
Takashima Y, Kikuchi E, Kikuchi J, Suzuki M, Kikuchi H, Maeda M, Shoji T,
Furuta M, Kinoshita I, Dosaka-Akita H, et al (2020) Bromodomain and
extraterminal domain inhibition synergizes with WEE1-inhibitor
AZD1775 effect by impairing nonhomologous end joining and enhancing
DNA damage in nonsmall cell lung cancer. Int J Cancer 146, 1114-1124.
van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sorensen M, Nielsen D, Schoffski
P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, et al (2021) A
first-in-man phase 1 study of the DNA-dependent protein kinase
inhibitor peposertib (formerly M3814) in patients with advanced solid
tumours. Br J Cancer 124, 728-735.
van Gent DC and Kanaar R (2016) Exploiting DNA repair defects for novel
cancer therapies. Mol Biol Cell 27, 2145-2148.
Vitale I, Galluzzi L, Castedo M and Kroemer G (2011) Mitotic catastrophe: a
mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12,
385-392.
Weaver BA (2014) How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 25,
2677-2681.
Yin S, Zeng C, Hari M and Cabral F (2012) Random mutagenesis of beta-tubulin
defines a set of dispersed mutations that confer paclitaxel
resistance. Pharm Res 29, 2994-3006.
Zeng X, Xu WK, Lok TM, Ma HT and Poon RYC (2019) Imbalance of the spindleassembly checkpoint promotes spindle poison-mediated cytotoxicity
with distinct kinetics. Cell Death Dis 10, 314.
Zhu L and Chen L (2019) Progress in research on paclitaxel and tumor
immunotherapy. Cell Mol Biol Lett 24, 40.
44
...
論文の公開元へ
